A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Matrix Metalloproteinase Inhibitors
  • Neoplasms
  • Tetracyclines

abstract

  • The recommended dose for Phase II studies of Col-3 administered once daily on an uninterrupted schedule is 50 mg/m2/day accompanied by efforts that promote adherence to the use of sunscreen and other photoprotective measures. Pharmacokinetic results indicate that plasma concentrations above biologically relevant concentrations are readily maintained at this dose, and additional disease-directed studies, particularly in patients with soft tissue sarcoma, should be considered.

publication date

  • October 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-04-0804

PubMed ID

  • 15475438

Additional Document Info

start page

  • 6512

end page

  • 21

volume

  • 10

number

  • 19